Teleflex lowers revenue outlook amid Biotronik integration delays

Teleflex Incorporated has lowered its 2026 revenue outlook, citing slower-than-expected integration of the Biotronik Vascular Intervention business. Despite this revision, the company reported that second-quarter continuing-operations revenue rose 28.9% year-over-year to $570.3 million.

CEO Jason Weidman noted that the integration delay is due to elongated timelines rather than issues with the underlying product portfolio. While the company reduced its full-year GAAP revenue growth forecast to between 13.4% and 14.4%, it increased its adjusted diluted earnings outlook to a range of $6.90 to $7.20 per share. This adjustment follows significant capital-allocation activities, including $250 million in share repurchases and the repayment of a $700 million term loan.

In separate investment news, Pzena Investment Management LLC acquired a significant new position in Teleflex during the second quarter. The firm purchased 603,206 shares, valued at approximately $76.46 million, representing about 1.36% of the medical technology company.